Singapore markets close in 6 minutes

Agile Therapeutics, Inc. (AGRX)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.3777-0.0218 (-5.47%)
At close: 03:40PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.59M
Enterprise value 2.20M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.04
Price/book (mrq)1.78
Enterprise value/revenue 0.11
Enterprise value/EBITDA -0.11

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-89.81%
S&P500 52-week change 326.49%
52-week high 34.2600
52-week low 30.2000
50-day moving average 30.4322
200-day moving average 31.4943

Share statistics

Avg vol (3-month) 3716.42k
Avg vol (10-day) 324.02k
Shares outstanding 56.86M
Implied shares outstanding 66.86M
Float 86.85M
% held by insiders 10.22%
% held by institutions 10.03%
Shares short (29 Feb 2024) 4222.1k
Short ratio (29 Feb 2024) 40.28
Short % of float (29 Feb 2024) 47.50%
Short % of shares outstanding (29 Feb 2024) 47.49%
Shares short (prior month 31 Jan 2024) 4189.89k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:50
Last split date 311 Apr 2023

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -36.24%
Operating margin (ttm)-48.23%

Management effectiveness

Return on assets (ttm)-75.71%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)21.5M
Revenue per share (ttm)6.96
Quarterly revenue growth (yoy)49.90%
Gross profit (ttm)N/A
EBITDA -15.54M
Net income avi to common (ttm)-7.79M
Diluted EPS (ttm)-6.7100
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.62M
Total cash per share (mrq)0.38
Total debt (mrq)378k
Total debt/equity (mrq)N/A
Current ratio (mrq)0.56
Book value per share (mrq)-1.51

Cash flow statement

Operating cash flow (ttm)-10.46M
Levered free cash flow (ttm)-5.94M